vs
Side-by-side financial comparison of CRISPR Therapeutics AG (CRSP) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.
CRISPR Therapeutics AG is the larger business by last-quarter revenue ($35.7M vs $28.8M, roughly 1.2× X4 Pharmaceuticals, Inc). X4 Pharmaceuticals, Inc runs the higher net margin — 1.0% vs -104.5%, a 105.5% gap on every dollar of revenue.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...
X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.
CRSP vs XFOR — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.7M | $28.8M |
| Net Profit | $-37.3M | $282.0K |
| Gross Margin | — | 83.6% |
| Operating Margin | -181.0% | -32.8% |
| Net Margin | -104.5% | 1.0% |
| Revenue YoY | -82.3% | — |
| Net Profit YoY | -141.8% | 100.5% |
| EPS (diluted) | $-0.41 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | — | $28.8M | ||
| Q4 24 | $35.7M | — | ||
| Q1 24 | — | $0 | ||
| Q4 23 | $201.2M | — | ||
| Q3 23 | $0 | $0 | ||
| Q2 23 | $70.0M | $0 | ||
| Q1 23 | $100.0M | — |
| Q1 25 | — | $282.0K | ||
| Q4 24 | $-37.3M | — | ||
| Q1 24 | — | $-51.8M | ||
| Q4 23 | $89.3M | — | ||
| Q3 23 | $-112.2M | $-2.3M | ||
| Q2 23 | $-77.7M | $-55.7M | ||
| Q1 23 | $-53.1M | — |
| Q1 25 | — | 83.6% | ||
| Q4 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q1 25 | — | -32.8% | ||
| Q4 24 | -181.0% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 34.6% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -136.0% | — | ||
| Q1 23 | -64.5% | — |
| Q1 25 | — | 1.0% | ||
| Q4 24 | -104.5% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 44.4% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -111.1% | — | ||
| Q1 23 | -53.1% | — |
| Q1 25 | — | $0.04 | ||
| Q4 24 | $-0.41 | — | ||
| Q1 24 | — | $-7.77 | ||
| Q4 23 | $1.12 | — | ||
| Q3 23 | $-1.41 | $-0.01 | ||
| Q2 23 | $-0.98 | $-0.33 | ||
| Q1 23 | $-0.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $40.3M |
| Total DebtLower is stronger | — | $75.0M |
| Stockholders' EquityBook value | $1.9B | $22.9M |
| Total Assets | $2.2B | $130.0M |
| Debt / EquityLower = less leverage | — | 3.27× |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $40.3M | ||
| Q4 24 | $1.9B | — | ||
| Q1 24 | — | $60.5M | ||
| Q4 23 | $1.7B | — | ||
| Q3 23 | $1.7B | $131.6M | ||
| Q2 23 | $1.8B | $136.4M | ||
| Q1 23 | $1.9B | — |
| Q1 25 | — | $75.0M | ||
| Q4 24 | — | — | ||
| Q1 24 | — | $55.0M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $55.0M | ||
| Q2 23 | — | $32.5M | ||
| Q1 23 | — | — |
| Q1 25 | — | $22.9M | ||
| Q4 24 | $1.9B | — | ||
| Q1 24 | — | $1.0M | ||
| Q4 23 | $1.9B | — | ||
| Q3 23 | $1.7B | $67.6M | ||
| Q2 23 | $1.8B | $67.5M | ||
| Q1 23 | $1.9B | — |
| Q1 25 | — | $130.0M | ||
| Q4 24 | $2.2B | — | ||
| Q1 24 | — | $112.2M | ||
| Q4 23 | $2.2B | — | ||
| Q3 23 | $2.1B | $173.3M | ||
| Q2 23 | $2.2B | $173.4M | ||
| Q1 23 | $2.2B | — |
| Q1 25 | — | 3.27× | ||
| Q4 24 | — | — | ||
| Q1 24 | — | 53.09× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 0.81× | ||
| Q2 23 | — | 0.48× | ||
| Q1 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.0M | $-12.4M |
| Free Cash FlowOCF − Capex | $-50.3M | — |
| FCF MarginFCF / Revenue | -140.9% | — |
| Capex IntensityCapex / Revenue | 0.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -43.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-325.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $-12.4M | ||
| Q4 24 | $-50.0M | — | ||
| Q1 24 | — | $-33.6M | ||
| Q4 23 | $-96.1M | — | ||
| Q3 23 | $-39.9M | $-68.8M | ||
| Q2 23 | $-133.2M | $-47.9M | ||
| Q1 23 | $8.8M | — |
| Q1 25 | — | — | ||
| Q4 24 | $-50.3M | — | ||
| Q1 24 | — | $-33.7M | ||
| Q4 23 | $-96.8M | — | ||
| Q3 23 | $-42.0M | $-68.8M | ||
| Q2 23 | $-136.8M | $-47.9M | ||
| Q1 23 | $5.7M | — |
| Q1 25 | — | — | ||
| Q4 24 | -140.9% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -48.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -195.4% | — | ||
| Q1 23 | 5.7% | — |
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.7% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.4% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 5.1% | — | ||
| Q1 23 | 3.1% | — |
| Q1 25 | — | -43.86× | ||
| Q4 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -1.08× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRSP
| Collaboration Revenue | $35.0M | 98% |
| Grant | $2.3M | 6% |
XFOR
Segment breakdown not available.
